Kim L. Clar

Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression

L. Zender, A. Hartkopf, H. Salih, 2022, Frontiers in Oncology.

Inhibition of NK Reactivity Against Solid Tumors by Platelet-Derived RANKL

P. Schneider, H. Salih, S. Maurer, 2019, Cancers.

The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma

H. Salih, B. Strunz, D. Dörfel, 2018, Cancer Immunology, Immunotherapy.

Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course

P. Schneider, H. Salih, Bastian J. Schmied, 2021, Cancers.

Platelet-expressed immune checkpoint regulator GITRL in breast cancer

L. Zender, A. Hartkopf, H. Salih, 2021, Cancer Immunology, Immunotherapy.

Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas

E. Malenke, H. Salih, Melanie Märklin, 2021, Frontiers in Immunology.

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

K. Wiesmüller, Melanie Märklin, A. Nelde, 2023, Nature communications.